You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Preclinical Development of Selective PKC_epsilon Inhibitors to Treat Alcoholism

    SBC: VM DISCOVERY, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Alcohol abuse and alcoholism (alcohol use disorders) are significant public health issues and represent one of the largest public health problems. In the United States alone, alcohol use disorders affect about 14 million people, costing approximately 184 billion a year due to lost wages, legal and medical costs from associated injuries and liver, cardiac, neop ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Responsible Drinking: Internet-based, Interactive Computer Tailored Intervention

    SBC: Pro-Change Behavior Systems, Inc.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Excessive alcohol use is associated with a range of serious and costly health, social, and economic consequences at the individual and societal level. This program of research serves as a venue by which to produce and test an innovative, science-based, and cost-effective means to intervene in a private, convenient, and individualized way with employed adults wh ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Expanding Healthcare Research Capacities through the Integration of Medicaid and

    SBC: ACUMEN LLC            Topic: NIA

    DESCRIPTION (provided by applicant): This STTR application requests funding to expand the capabilities of Acumen LLC's Medicare/Medicaid Research Information Center (MedRIC). To advance the quality of the data available for public policy research, MedRIC facilitates the acquisition of data from the Centers for Medicare and Medicaid Services (CMS) to participants of surveys and registries spon ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Protective biomarkers for the development of vaccines against malaria

    SBC: ImmPORT Therapeutics Inc dba Antigen Discovery Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): For the Phase I SBIR grant we constructed a Plasmodium falciparum (Pf) 3D7 protein microarray containing 2,320 individual polypeptides representing 1,200 known and hypothetical proteins, or ~23 % of the entire Pf proteome. We showed that the individual proteins printed on those arrays captured antibodies present in sera from infected individuals and the amount ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. An Orally Delivered Booster Vaccine Candidate for Hepatitis B

    SBC: Applied Biotechnology Institute, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): There are 350 million people chronically infected with hepatitis B virus who have a high risk for cirrhosis of the liver and liver cancer resulting in approximately a million deaths annually. This is an alarming rate asthere has been a safe and efficacious vaccine on the market for more than twenty years. High costs of production, distribution and administratio ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. A fully integrated assay and platform for detecting Clostridium difficile.

    SBC: CLAREMONT BIOSOLUTIONS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The primary goal of this proposed project is to develop a point-of-care diagnostic assay and platform for the detection of Clostridium difficile from human stool. Two additional goals are to detect the hypervirulent strain of C. difficile B1/NAP/027 and to detect C. difficile spores from swabs of medical devices. C. difficile associated disease (CDAD) is now th ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. An Integrated Diagnostic System for Rapid Antimicrobial Susceptibility Testing

    SBC: GeneFluidics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Pathogens responsible for many of the common human infectious diseases such as urinary tract infection (UTI), gastroenteritis, pneumonia, and wound infections have proven to be highly adept in acquiring mechanisms of antimicrobial resistance. Widespread injudicious practice of empiric antibiotic usage by healthcare providers and infiltration of antibiotics in ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Soluble high-affinity T cell receptors prevent MRSA lethality

    SBC: IMMUVEN, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Methicillin resistant Staphylococcus aureus (MRSA) and methicillin sensitive S. aureus (MSSA) are highly significant human health threats that are responsible for a range of diseases. Recently, the CDC and colleagues reported that MRSA are the most significant causes of serious infections and infectious disease deaths in the United States. A major factor involv ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  9. A Therapeutic Vaccine for Chronic Hepatitis B

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The objective of this proposal is to assess the feasibility of using recombinant virus-like- particles (VLPs) to elicit neutralizing antibodies and prime CD4+ T cells reactive with hepatitis B viral (HBV) antigens as candidate immunotherapeutics for chronic HBV infection. For this purpose, we have defined 8 neutralizing B cell epitopes from the HBV envelope Pr ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  10. A therapeutic Fc gamma Fel d1 chimeric protein vaccine to treat cat allergy

    SBC: TUNITAS THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to develop and commercialize a novel biologic for allergen- specific immunotherapy as effective treatment for cat allergy/asthma. Cat allergy is common, with 17% of USpopulation, age 6-59, being skin test positive for cat and 60% of those individuals have symptoms when exposed to cat dander Cat allergen, Fel d1 ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government